Your email has been successfully added to our mailing list.

×
0.137440758293839 0.137440758293839 0.137440758293839 0.188625592417062 0.0374407582938388 0.0663507109004739 0.0805687203791469 0.099526066350711
Stock impact report

Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint

STEMLINE THERAPEUTICS (STML) 
Last stemline therapeutics earnings: 3/13 04:45 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.stemline.com/investor-relations
Company Research Source: GlobeNewswire
Detailed results will be presented at the ASH 2017 Annual Meeting (Dec. 9-12)Based on FDA feedback, BLA filing remains on-track Conference call scheduled for today, Tuesday, October 31, 2017 at 8:30AM ET NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that the pivotal Phase 2 trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has met its primary endpoint. Based on feedback from the U.S. Food and Drug Administration (FDA), Stemline remains on track to begin submission of its Biologics License Application (BLA) in the 4Q17-1Q18 timeframe. SL-401 has been granted Breakthrough Therapy Designation (BTD) by the FDA for the treatment of BPDCN, and Orphan Drug Designation (ODD) by the FDA and EU for the treatment of patients with BPDCN and acute myeloid leukemia (AML). Pivotal TrialThe pivotal Phase 2 trial of Show less Read more
Impact Snapshot
Event Time:
STML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for STML alerts
Opt-in for
STML alerts

from News Quantified
Opt-in for
STML alerts

from News Quantified